Effect of intraoperative infusion of dexmedetomidine on postoperative recovery in patients undergoing endovascular interventional therapies: A prospective, randomized, controlled trial

摘要: BACKGROUND Rapid emergence from general anesthesia during endovascular interventional therapies (EITs) is important. However, the solution that improved quality of both analepsia and postoperative recovery after EITs has not been specifically addressed. We conducted this prospective, randomized, controlled trial to evaluate intraoperative infusion dexmedetomidine on analepsia and in patients undergoing EITs. METHODS Eighty-six were divided into three groups: RD1 (dexmedetomidine at an initial dose 0.5 μg/kg for 10 min adjusted 0.2 μg kg-1  hr-1 throughout EIT), RD2 0.4 μg kg-1 RD3 0.6 μg kg-1 EIT). An analgesia system delivered sufentanil only. The primary outcome measure was total consumption nimodipine first 48 hr surgery. secondary measures consumption, pain intensity, hemodynamics, functional activity score (FAS), neurologic examination, level sedation (LOS), Bruggrmann comfort scale (BCS). also recorded hemodynamic data, requirement narcotic vasoactive drugs, prevalence complications symptomatic cerebral vasospasm, duration postanesthesia care unit (PACU) stay, Glasgow Outcome Score (GOS) 3 months, infarction 30 days RESULTS Dexmedetomidine application regimen reduced surgery, drugs intensity 8 hr increased BCS 4 hr surgery stability. LOS 0.5 hr surgeon satisfaction lower. There no significant differences among groups except urapidil, coma (GCS) FAS GOS 30 days. CONCLUSIONS (an 0.5 μg/kg 10 min 0.6 μg kg-1 hr-1 EIT) could reduce opioid 48 hr concerning adverse effects, improve scores. optimal dosage merits further investigation.